Zevra Therapeutics, Inc. develops therapeutics for patients with rare diseases, focusing on conditions such as Niemann-Pick disease type C and urea cycle disorders. The company aims to address unmet medical needs through scientific advancements and is engaged in clinical trials to bring its products, including MIPLYFFA® and OLPRUVA®, to market. Zevra operates primarily in the biotechnology sector, targeting patients and caregivers affected by rare diseases.
- Website
- zevra.com
- Issuer profile
- All listings